布鲁顿激酶抑制剂在慢性淋巴细胞白血病中的应用
Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia.
作者信息
Gozzetti Alessandro, Candi Veronica, Brambilla Corrado Zuanelli, Papini Giulia, Fabbri Alberto, Bocchia Monica
机构信息
Department of hematology, Azienda Ospedaliera Universitaria Senese, Policlinico S. Maria alle Scotte, viale Bracci 16, 53100 Siena, Italy.
Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, Italy.
出版信息
Anticancer Agents Med Chem. 2017;17(8):1040-1045. doi: 10.2174/1871520616666160928153342.
Abnormality of the B-cell receptor (BCR) signaling is correlated to origin of many B-cell malignancies. Bruton's tyrosine kinase (BTK), is described as a possible target in a many B-cell neoplasms. Ibrutinib is the most used inhibitor of BTK and has great tolerability and efficacy in chronic lymphocytic leukemia. This review summarizes results with ibrutinib in clinical trials and novel BTK inhibitors of interest.
B细胞受体（BCR）信号异常与许多B细胞恶性肿瘤的起源相关。布鲁顿酪氨酸激酶（BTK）被认为是许多B细胞肿瘤的潜在靶点。伊布替尼是最常用的BTK抑制剂，在慢性淋巴细胞白血病中具有良好的耐受性和疗效。本文综述了伊布替尼在临床试验中的结果以及其他相关的新型BTK抑制剂。
Zotero 插件